Association of Thromboxane Generation With Survival in Aspirin Users and Nonusers

Persistent systemic thromboxane generation, predominantly from nonplatelet sources, in aspirin (ASA) users with cardiovascular disease (CVD) is a mortality risk factor. This study sought to determine the mortality risk associated with systemic thromboxane generation in an unselected population irres...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology Vol. 80; no. 3; p. 233
Main Authors: Rade, Jeffrey J, Barton, Bruce A, Vasan, Ramachandran S, Kronsberg, Shari S, Xanthakis, Vanessa, Keaney, Jr, John F, Hamburg, Naomi M, Kakouros, Nikolaos, Kickler, Thomas A
Format: Journal Article
Language:English
Published: United States 19.07.2022
Subjects:
Aged
Aspirin - therapeutic use
Cardiovascular Diseases
Creatinine
Female
Humans
Male
Middle Aged
Thromboxane B2
Thromboxanes - metabolism
thromboxane
mortality
aspirin
isoprostane
platelets
ISSN:1558-3597, 1558-3597
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Persistent systemic thromboxane generation, predominantly from nonplatelet sources, in aspirin (ASA) users with cardiovascular disease (CVD) is a mortality risk factor. This study sought to determine the mortality risk associated with systemic thromboxane generation in an unselected population irrespective of ASA use. Stable thromboxane B metabolites (TXB -M) were measured by enzyme-linked immunosorbent assay in banked urine from 3,044 participants (mean age 66 ± 9 years, 53.8% women) in the Framingham Heart Study. The association of TXB -M to survival over a median observation period of 11.9 years (IQR: 10.6-12.7 years) was determined by multivariable modeling. In 1,363 (44.8%) participants taking ASA at the index examination, median TXB -M were lower than in ASA nonusers (1,147 pg/mg creatinine vs 4,179 pg/mg creatinine; P < 0.0001). TXB -M were significantly associated with all-cause and cardiovascular mortality irrespective of ASA use (HR: 1.96 and 2.41, respectively; P < 0.0001 for both) for TXB -M in the highest quartile based on ASA use compared with lower quartiles, and remained significant after adjustment for mortality risk factors for similarly aged individuals (HR: 1.49 and 1.82, respectively; P ≤ 0.005 for both). In 2,353 participants without CVD, TXB -M were associated with cardiovascular mortality in ASA nonusers (adjusted HR: 3.04; 95% CI: 1.29-7.16) but not in ASA users, while ASA use was associated with all-cause mortality in those with low (adjusted HR: 1.46; 95% CI: 1.14-1.87) but not elevated TXB -M. Systemic thromboxane generation is an independent risk factor for all-cause and cardiovascular mortality irrespective of ASA use, and its measurement may be useful for therapy modification, particularly in those without CVD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1558-3597
1558-3597
DOI:10.1016/j.jacc.2022.04.034